Dr. David Elkayam, MD

Dr. Elkayam practices at Bellingham Asthma Allergy Immunology Clinic PS in Bellingham, Washington.

Dr. Elkayam's NPI, 1871589234, was assigned on September 21, 2005. Dr. Elkayam graduated from Icahn School Of Medicine At Mount Sinai in 1982. Dr. Elkayam holds New York license 25387.

Dr. Elkayam's primary practice is Bellingham Asthma Allergy Immunology Clinic PS, at 3015 Squalicum Pkwy, Bellingham, WA 98225 in Whatcom County. The practice phone is (360) 733-5733.

Dr. Elkayam's primary practice is Bellingham Asthma Allergy Immunology Clinic PS in Bellingham, Washington. Dr. Elkayam is also affiliated with PeaceHealth St. Joseph Medical Center. The medical group on file is Bellingham Asthma, Allergy & Immunology Clinic. Dmand AI also links Dr. Elkayam to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Elkayam practices, 2 sites in all. Vendor and product names are available with a free account.

Allergy and immunology is Dr. Elkayam's primary specialty in the NPI Registry, under taxonomy code 207K00000X. Dr. Elkayam is board certified in allergy & immunology by the American Board of Allergy and Immunology. Dmand AI has Dr. Elkayam's licenses on file in 3 states: New York, Washington and Colorado.

Dmand AI lists acute sinusitis, asthma, chronic nasal allergies, chronic sinusitis, hives and immune deficiency disease among the conditions Dr. Elkayam treats.

CMS data shows 2,271 Medicare services from Dr. Elkayam across 14 procedure codes in 2024, for 183 Medicare patients. Medicare paid $40,887 for them. Every service was in an office.

CMS counts 183 Medicare patients who saw Dr. Elkayam in 2024. The largest group is 65 to 74, with 116 patients. 66% of them have high cholesterol, and 55% have high blood pressure. Their average risk score is 0.91, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Elkayam's median patient age at 49, with 64% women.

In 2024, Dr. Elkayam wrote 450 Medicare Part D claims for 129 patients. 56% of them were for generic drugs. CMS names the drug for 332 of them, across 15 drugs with 11 or more claims each, at $110,322 in total drug cost. In 2023, CMS named 419 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Elkayam for performance year 2024, reported as part of a group. Dr. Elkayam accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Elkayam as offering telehealth.

Dmand AI links 6 papers to Dr. Elkayam, published from 2017 to 2025. 2022 was the busiest year, with 2. The most frequent topics are Nasal Polyps, Fluticasone and Rhinitis. Dr. Elkayam has published most often in J Allergy Clin Immunol. Dr. Elkayam's most frequent co-authors are Ramy A. Mahmoud, MD, MPH, Harry Jack Sacks, MD and Fuad M. Baroody.

Dmand AI links Dr. Elkayam to 5 clinical trials, 3 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Asthma, Bruton type agammaglobulinemia and Common Variable Immunodeficiency. Bio Products Laboratory sponsors the most, 2. Open Payments lists research payments to Dr. Elkayam that name 2 trials.

CMS Open Payments shows 250 general payments to Dr. Elkayam from 33 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 46% of the total. Consortium of Independent Immunology Clinics, LLC paid the most, $18,600. It also lists 23 research payments totaling $87,936 from 2016 to 2017, naming 2 clinical trials.

Dmand AI lists 1 award for Dr. Elkayam, most recently CMS Stage 1 2012 in 2011.

Dr. Elkayam graduated from Icahn School Of Medicine At Mount Sinai in 1982. Dr. Elkayam is a member of AAAAI.

Dr. Elkayam is in network with 17 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.